FOUNDATIONONE®LIQUID CDx

PATIENT

TUMOR TYPE
Pancreas cancer (NOS)
COUNTRY CODE
PE

REPORT DATE
16 Mar 2021
ORDERED TEST #
ORD-1038606-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT

DISEASE Pancreas cancer (NOS)

DATE OF BIRTH 24 January 1956
SEX Female
MEDICAL RECORD # Not given

PHYSICIAN

MEDICAL FACILITY Arias Stella
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 317319
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN ID B.C.B.V 01/24/1956
SPECIMEN TYPE Blood
DATE OF COLLECTION 02 March 2021
SPECIMEN RECEIVED 10 March 2021

Biomarker Findings

Blood Tumor Mutational Burden - 0 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Cannot Be Determined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS G12D
DNMT3A W305*, Q573*
TP53 R342fs*5

0 Therapies with Clinical Benefit
0 Therapies with Lack of Response
2 Clinical Trials

BIOMARKER FINDINGS

Blood Tumor Mutational Burden - 0 Muts/Mb

Microsatellite status - MSI-High Not Detected

Tumor Fraction - Cannot Be Determined

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is an estimate of the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample based on observed aneuploid instability.

GENOMIC FINDINGS		VAF %
KRAS -	G12D	1%
2 Trials see p. 6		

THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
None	None

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

DNMT3A - W305*, Q573* p. 4
TP53 - R342fs*5 p. 5

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *BRCA1*, *BRCA2*, *BRIP1*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF2*, *PALB2*, *PMS2*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1038606-01 VAF%
Blood Tumor Mutational Burden		0 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Cannot Be Determined
KRAS	● G12D	1%
DNMT3A	● Q573*	0.46%
	● W305*	0.46%
TP53	● R342fs*5	0.25%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)[5-7]. Published data investigating the prognostic implications of bTMB levels in pancreatic carcinoma are limited (PubMed, Jul 2020). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69-314 months) compared to those with lower TMB (average of 5.7 mutations; 10-42 months)[8].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[9-10] and cigarette smoke in lung cancer[11-12], treatment with temozolomide-based chemotherapy in glioma[13-14], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[15-19], and microsatellite instability (MSI)[15,18-19]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Cannot Be Determined

POTENTIAL TREATMENT STRATEGIES

Specimens with high tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[20-25].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[26]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[27], Ewing sarcoma and osteosarcoma[28], prostate cancer[23], breast cancer[29], leiomyosarcoma[30], esophageal cancer[31], colorectal cancer[32], and gastrointestinal cancer[33].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[34], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[35-36]. However, the tumor fraction estimate in this sample could not be determined with confidence.

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
KRAS

ALTERATION
G12D

TRANSCRIPT ID
NM_004985

CODING SEQUENCE EFFECT
35G>A

POTENTIAL TREATMENT STRATEGIES
Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[37-42]. Initial Phase 1 monotherapy trials of MEK inhibitors in patients with pancreatic cancer showed promise, with DCR (PR and/or SD) up to 37%[43], response rates up to 25%[43-47], and prolonged PRs in certain patients[44,46,48]. However, subsequent clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status[49-52], with refametinib and gemcitabine even showing a trend towards worse response and survival in patients with KRAS-mutant pancreatic tumors than in those with KRAS wild-type tumors (OS 6.6 months vs 18.2 months)[49]. Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors[53] or PI3K-AKT pathway inhibitors[54-55], reported no PRs and frequent adverse events in patients with KRAS-mutant pancreatic cancer. Emerging preclinical studies suggest MEK inhibition downstream of KRAS-mutant pancreatic tumors leads to increased autophagy[56-57]. Combination MEK/autophagy inhibitors may therefore be more beneficial. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine exhibited a PR[56]. The reovirus Reolysin targets cells with activated RAS signaling[58-60] and is in clinical trials in patients with some tumor types. Reolysin has demonstrated mixed clinical efficacy, with the highest rate of response reported for patients with head and neck cancer[61-69]. A Phase 2 trial of paclitaxel/carboplatin with or without Reolysin in patients with metastatic pancreatic adenocarcinoma reported no improvement in PFS with addition of Reolysin, regardless of KRAS mutational status[70]; however a Phase 2 study of Reolysin and gemcitabine in patents with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs in 34 patients with a favorable median OS of 10.2 months[71].

FREQUENCY & PROGNOSIS
KRAS mutations have been observed in 91-95% of pancreatic ductal adenocarcinoma cases[72-73], with the majority of mutations found at codon 12[74-77]. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma[75].

FINDING SUMMARY
KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[38,78]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, and K117N have been characterized as activating and oncogenic[38,79-100].

GENE
DNMT3A

ALTERATION
W305*, Q573*

TRANSCRIPT ID
NM_022552, NM_022552

CODING SEQUENCE EFFECT
914G>A, 1717C>T

POTENTIAL TREATMENT STRATEGIES
There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS
DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2021)[5-6]. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2021). Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[101-106]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[101-102]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[107]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[105,108-109]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

FINDING SUMMARY
The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation[110-111]. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor[112-117]. Alterations such as seen here may disrupt DNMT3A function or expression[118-121].

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
R342fs*5

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
1022_1023insT

POTENTIAL TREATMENT STRATEGIES

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[122-125], or p53 gene therapy and immunotherapeutics such as SGT-53[126-130] and ALT-801[131]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild-type[132]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[133]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum-refractory TP53-mutated ovarian cancer[134]. The combination of adavosertib with paclitaxel and carboplatin in patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[135]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel[136]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations[137]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[130]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutated, but not TP53-wild-type, breast cancer xenotransplant mouse model[138]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[139-140]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[141-142]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 33-75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases[72,143-145]. TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis[146-147]. Additionally, aberrant expression of p53 has been found in 54-81% of pancreatic ductal adenocarcinoma cases[144,148-150]. Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis[148,151-152]. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[101-106]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[101-102]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[107]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[105,108-109]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[153]. Alterations such as seen here may disrupt TP53 function or expression[154-158].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[159-161], including sarcomas[162-163]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[164] to 1:20,000[163]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[165]. In the appropriate clinical context, germline testing of TP53 is recommended.

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
KRAS

ALTERATION
G12D

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant pancreatic cancer. Emerging data suggest patients with KRAS-mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors.

NCT04132505

PHASE 1

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Texas

NCT03825289

PHASE 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Utah

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CDKN1B A121V	***DNMT3A*** R720L	***MLH1*** R9W	***MLL2*** R3342C
MSH6 E30K	***TSC1*** M322T	***VHL*** E42K	

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** (MEK1) Exons 2, 3	***MAP2K2*** (MEK2) Exons 2-4, 6, 7	*MAP2K4*	*MAP3K1*	*MAP3K13*

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WTI*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also detects select genomic rearrangements, select copy number alterations, tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF ALTERATIONS AND THERAPIES

Biomarker and Genomic Findings

Therapies are ranked based on the following criteria: Therapies with clinical benefit in patient's tumor type (ranked alphabetically within each NCCN category) followed by therapies with clinical benefit in other tumor type (ranked alphabetically within each NCCN category).

Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from observed aneuploid instability in the sample.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters with no conflicts), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *BAP1, BRCA1, BRCA2, BRIP1, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories please refer to the NCCN Compendium®.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 3.0.0

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
6. Gao J, et al. Sci Signal (2013) pmid: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
8. Hu et al., 2017; ASCO Abstract e15791
9. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
10. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
11. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
12. Rizvi NA, et al. Science (2015) pmid: 25765070
13. Johnson BE, et al. Science (2014) pmid: 24336570
14. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
15. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
16. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
17. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
18. Nature (2012) pmid: 22810696
19. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
20. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
21. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
22. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
23. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
24. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
25. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
26. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
27. Lapin M, et al. J Transl Med (2018) pmid: 30400802
28. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
29. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
30. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
31. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
32. Fan G, et al. PLoS ONE (2017) pmid: 28187169
33. Vu et al., 2020; DOI: 10.1200/PO.19.00204
34. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
35. Zhang EW, et al. Cancer (2020) pmid: 32757294
36. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
37. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
38. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
39. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
40. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
41. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
42. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
43. Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619
44. Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017
45. Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947
46. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
47. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
48. Garrido-Laguna I, et al. Oncoscience (2015) pmid: 25897431
49. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
50. Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440
51. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
52. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
53. Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290
54. Chung V, et al. JAMA Oncol (2017) pmid: 27978579
55. Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057
56. Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748
57. Bryant KL, et al. Nat. Med. (2019) pmid: 30833752
58. Strong JE, et al. EMBO J. (1998) pmid: 9628872
59. Coffey MC, et al. Science (1998) pmid: 9812900
60. Gong J, et al. Front Oncol (2014) pmid: 25019061
61. Forsyth P, et al. Mol. Ther. (2008) pmid: 18253152
62. Vidal L, et al. Clin. Cancer Res. (2008) pmid: 18981012
63. Gollamudi R, et al. Invest New Drugs (2010) pmid: 19572105
64. Harrington KJ, et al. Clin. Cancer Res. (2010) pmid: 20484020
65. Comins C, et al. Clin. Cancer Res. (2010) pmid: 20926400
66. Lolkema MP, et al. Clin. Cancer Res. (2011) pmid: 21106728
67. Galanis E, et al. Mol. Ther. (2012) pmid: 22871663
68. Karapanagiotou EM, et al. Clin. Cancer Res. (2012) pmid: 22316603
69. Morris DG, et al. Invest New Drugs (2013) pmid: 22886613
70. Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845
71. Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479
72. Biankin AV, et al. Nature (2012) pmid: 23103869
73. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
74. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196
75. Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280
76. Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602
77. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325
78. Kahn S, et al. Anticancer Res. () pmid: 3310850
79. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
80. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
81. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
82. Sci. STKE (2004) pmid: 15367757
83. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
84. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
85. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
86. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
87. Kim E, et al. Cancer Discov (2016) pmid: 27147599
88. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
89. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
90. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
91. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
92. Scheffzek K, et al. Science (1997) pmid: 9219684
93. Scholl C, et al. Cell (2009) pmid: 19490892
94. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
95. Tyner JW, et al. Blood (2009) pmid: 19075190
96. Valencia A, et al. Biochemistry (1991) pmid: 2029511
97. White Y, et al. Nat Commun (2016) pmid: 26854029
98. Wiest JS, et al. Oncogene (1994) pmid: 8058307
99. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
100. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
101. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
102. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
103. Xie M, et al. Nat. Med. (2014) pmid: 25326804
104. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
105. Severson EA, et al. Blood (2018) pmid: 29678827
106. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
107. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
108. Chabon JJ, et al. Nature (2020) pmid: 32269342
109. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
110. Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773
111. Prog Mol Biol Transl Sci (2011) pmid: 21507354
112. Yang J, et al. Mol Med Rep () pmid: 21887466
113. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
114. Daskalos A, et al. Cancer (2011) pmid: 21351083
115. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317
116. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581
117. Kim MS, et al. APMIS (2013) pmid: 23031157
118. Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382
119. Guo X, et al. Nature (2015) pmid: 25383530
120. Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090
121. Zhang ZM, et al. Nature (2018) pmid: 29414941
122. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
123. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
124. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
125. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
126. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
127. Xu L, et al. Mol. Med. (2001) pmid: 11713371
128. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
129. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
130. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
131. Hajdenberg et al., 2012; ASCO Abstract e15010
132. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
133. Moore et al., 2019; ASCO Abstract 5513
134. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
135. Oza et al., 2015; ASCO Abstract 5506
136. Lee J, et al. Cancer Discov (2019) pmid: 31315834
137. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
138. Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188
139. Kwok M, et al. Blood (2016) pmid: 26563132
140. Boudny M, et al. Haematologica (2019) pmid: 30975914
141. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
142. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
143. Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721
144. Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051
145. Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330
146. Iacobuzio-Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692
147. Macgregor-Das AM, et al. J Surg Oncol (2013) pmid: 22806689
148. Oshima M, et al. Ann. Surg. (2013) pmid: 23470568
149. Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431
150. Tsiambas E, et al. J BUON () pmid: 20414934

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

151. Ansari D, et al. Br J Surg (2011) pmid: 21644238
152. Grochola LF, et al. Pancreas (2011) pmid: 21404460
153. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
154. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
155. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
156. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
157. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
158. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
159. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
160. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
161. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
162. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
163. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
164. Lalloo F, et al. Lancet (2003) pmid: 12672316
165. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713

Electronically signed by Brennan Decker, M.D., Ph.D. | 16 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531